[Methotrexate-leucovorin rescue therapy: pharmacological characteristics and clinical effective use]
- PMID: 8978794
[Methotrexate-leucovorin rescue therapy: pharmacological characteristics and clinical effective use]
Abstract
An antifolate first introduced into the clinic about half decades ago, Methotrexate is effective against a variety of human cancers, when administered alone or in combination with leucovorin rescue at wide-ranging doses and by many different schedules. We know much more about MTX and its molecular and cellular pharmacology and mechanisms of anti-cancer action in light of current knowledge of the biochemistry of folate. This understanding has stimulated novel approaches to the clinical application of the drug and has greatly enhanced its therapeutic efficacy.
Similar articles
-
"Rescue" techniques in cancer chemotherapy: use of leucovorin and other rescue agents after methotrexate treatment.Semin Oncol. 1977 Jun;4(2):203-16. Semin Oncol. 1977. PMID: 301662 No abstract available.
-
"Single"-agent activity of high-dose methotrexate with citrovorum factor rescue.Cancer Treat Rep. 1978 Feb;62(2):233-5. Cancer Treat Rep. 1978. PMID: 305823 No abstract available.
-
Population pharmacokinetics of high-dose methotrexate after intravenous administration in pediatric patients with osteosarcoma.Ther Drug Monit. 2009 Feb;31(1):76-85. doi: 10.1097/FTD.0b013e3181945624. Ther Drug Monit. 2009. PMID: 19077931
-
High-dose methotrexate and/or leucovorin rescue for the treatment of children with lymphoblastic malignancies: do we really know why, when and how?Neoplasma. 2005;52(6):456-63. Neoplasma. 2005. PMID: 16284689 Review.
-
Understanding and managing methotrexate nephrotoxicity.Oncologist. 2006 Jun;11(6):694-703. doi: 10.1634/theoncologist.11-6-694. Oncologist. 2006. PMID: 16794248 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources